Eton Pharmaceuticals, Inc. Total Long-Term Debt
Eton Pharmaceuticals, Inc. (ETON) had Total Long-Term Debt of $29.99 million as of 2025-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Balance Sheet › Liabilities › Debt
us-gaap:LongTermDebt · last filed 2025-05-13
- 2025-03-31: Long-term Debt $29.99M.
- 2024-12-31: Long-term Debt $29.81M.
- 2023-12-31: Long-term Debt $0.00.
- 2023-09-30: Long-term Debt $4.20M.
| Period end | Long-term Debt |
|---|---|
| 2025-03-31 | $29.99M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $29.81M 10-Q · filed 2025-05-13 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-18 |
| 2023-09-30 | $4.20M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $4.55M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $5.11M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $5.38M 10-K · filed 2024-03-14 |
| 2022-09-30 | $5.68M 10-Q · filed 2022-11-10 |
| 2022-06-30 | $5.99M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $6.33M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $5.26M 10-K · filed 2023-03-16 |
| 2021-09-30 | $5.55M 10-Q · filed 2021-11-16 |
| 2021-06-30 | $5.86M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $6.18M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $6.53M 10-K · filed 2022-03-16 |
| 2020-09-30 | $6.50M 10-Q · filed 2020-11-12 |
| 2020-06-30 | $4.59M 10-Q · filed 2020-08-12 |
| 2020-03-31 | $4.57M 10-Q · filed 2020-05-14 |
| 2019-12-31 | $4.54M 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |